CTOs on the Move

Virtus Pharmaceuticals

www.virtusrx.com

 
Virtus Pharmaceuticals’ mission is to be the leading specialty niche pharmaceutical company providing the highest quality products through experienced leadership, innovative approaches and outstanding customer service.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.virtusrx.com
  • 2649 Causeway Center Drive
    Tampa, FL USA 33619
  • Phone: 813.283.1344

Executives

Name Title Contact Details

Similar Companies

Regulatory and Clinical Research Institute

Regulatory and Clinical Research Institute, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UroLift

The UroLift System is an FDA Cleared, revolutionary minimally invasive treatment of Benign Prostatic Hyperplasia (BPH) or an enlarged prostate.

Lexigen

Lexigen is a Nashua, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Havas Health and You

Havas Health & You is a unique health and wellness network focused on promoting healthy living decisions across the entire health ecosystem. We believe in putting YOU – our employees, business partners, and our customers – at the center of everything we do. By understanding what you need and crafting unique solutions, we can help you stay and live well.

Oyster Point Pharma

Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.